Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Open accessThe DOI matches its Crossref record; 161 of the 164 references it cites were found in a registry or an index.
Abstract
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable treatment of metabolic dysfunction is bariatric surgery, necessitating the development of unique therapeutics. GLP-1 is structurally related to glucagon and glucose-dependent insulinotropic peptide (GIP), allowing for the development of intermixed, unimolecular peptides with activity at each of their respective receptors. In this review, we discuss the range of tissue targets and added benefits afforded by the inclusion of each of GIP and glucagon. We discuss considerations for the development of sequence-intermixed dual agonists and triagonists, highlighting the importance of evaluating balanced signaling at the targeted receptors. Several multireceptor agonist peptides have been developed and evaluated, and the key preclinical and clinical findings are reviewed in detail. The biological activity of these multireceptor agonists are founded in the success of GLP-1-directed strategies; by including GIP and glucagon components, these multireceptor agonists are thought to enhance GLP-1’s activities by broadening the tissue targets and synergizing at tissues that express multiple receptors, such at the brain and pancreatic isletβ cells. The development and utility of balanced, unimolecular multireceptor agonists provide both a useful tool for querying the actions of incretins and glucagon during metabolic disease and a unique drug class to treat type 2 diabetes with unprecedented efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, this multi-receptor agonism approach to weight loss was hindered by commercial considerations of production and formulation [45], the biological impasse that glucagon potently induces hyperglycemia [56,57], and potential dose-limiting cardiovascular liabilities arising from positive chronotropic actions to influence hemodynamic parameters [58].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“These compounds, termed triagonists or triple agonists, couple the weight-reducing efficacy of GLP-1R, GIPR, and GcgR agonism while simultaneously buffering the glycemic effects of Gcg with dual incretin receptor activation [43,45].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [45]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In particular, it inhibits hepatic synthesis and promotes beta-oxidation of fatty acids [148,150] and, probably, lipolysis in adipose tissue [151].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [148]
Experimental — accuracy not yet measuredIn the citing paper
“However, glucagon counteracts the insulin action, promoting gluconeogenesis and hepatic glycogenolysis [148].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Cited by
Items 101–152 of 152
Triple G Agonists — A Home Run for Obesity?
Patti, M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307282 · Cited by 7
Cooper-Leavitt, E. T., Shin, M. J., Beus, C. G., Chiu, A. T., Parker, G., Radford, J. H., Evans, E. P., Edwards, I. T., Arroyo, J. A., Reynolds, P. R., et al. (2025) · Nutrients · doi:10.3390/nu17040625 · Cited by 8
“Incretin-targeted therapies have become a cornerstone of T2DM management, with GLP-1 receptor agonists demonstrating robust efficacy in improving glycemic control and promoting weight loss [1,8,9].”
Elsaigh, M., Awan, B., Shabana, A., Sohail, A., Asqalan, A., Saleh, O., Szul, J., Khalil, R., Elgohary, H., Marzouk, M., et al. (2024) · Cureus · doi:10.7759/cureus.52796 · Cited by 7
“Both procedures made considerable weight loss and remission of obesity-related comorbidities [14].”
BackgroundPal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
Tratamiento farmacológico de la obesidad para médicos de Atención Primaria
Rubio, M. Á., Fernández-García, J. M., Andújar, R. C., Altozano, C. S., & Carpi, J. J. U. (2019) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.04.005 · Cited by 19
Camins, A., Ettcheto, M., Busquets, O., Manzine, P. R., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., Sureda, F. X., Bulló, M., Olloquequi, J., et al. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552677 · Cited by 5
“HM15211 and MAR423 are singlemolecule peptides that reduce diabetic complications in rodent models of obesity [15].”
BackgroundDelobel, M., & Dalle, S. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.09.010 · Cited by 7
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“Other approaches include the development of a hybrid GIP-OXM peptide by replacing residues from the N-terminal of OXM with D-Ala-GIP (DA2GIPOXM) [75] or triagonists derived from the three endogenous hormone peptide sequences ([DAla2]GLP-1/glucagon) [25].”
BackgroundMethodInfluentialBruner, K. R., Byington, I. R., Marx, T. J., Vasileva, A., Fletcher, T., Ghimire, S., Zappia, I. J., Shaju, Y., Zeng, J., Wachsmuth, H. R., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01899-w · Cited by 8
“Numerous research groups and the pharmacological industry have shown the potential of glucagon containing di-and tri-agonists to treat obesity, diabetes, and the associated metabolic dysfunction [29, 30, 96].”
Taylor, S. I., Montasser, M. E., Yuen, A. H., Fan, H., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Muniyappa, R., Streeten, E. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15143 · Cited by 6
“Recent literature has suggested the existence of positive crosstalk among GLP-1, GIP and glucagon with respect to their beneficial effects on insulin secretion and weight loss.(36) These considerations led to the design of tirzepatide—a recently approved ‘twincretin’ combining agonist activity against both GLP-1R and…”
BackgroundD’Souza, N. C., ALEALI, N., Shakeri, D., ATHERLEY, S. C., Hoffman, E. G., KARIMI-CHAHARTASH, S., JAVANBAKHSH, S., Chan, O. T. M., Liggins, R., & Riddell, M. C. (2026) · Endocrinology · doi:10.1210/endocr/bqaf192 · Cited by 4
Carr, E. R., Higgins, P. B., McClenaghan, N. H., Flatt, P. R., & McCloskey, A. G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171196 · Cited by 4
“Recently, research surrounding glucagon has intensified, particularly due to interest in its application in the development of new therapies for T2D, with glucagon/GIP/GLP-1 receptor dual and triple agonists currently undergoing clinical trials [15,20,4,79].”
BackgroundSatheesh, G., Asokan, A. K., Vijayakumar, G., Chandran, M., Surendran, A., Simon, L., & Jaleel, A. (2025) · Metabolomics · doi:10.1007/s11306-025-02295-3 · Cited by 4
“(Capozzi et al., 2018; McLaughlin et al., 2004).”
Morales, J., & Assumpcao‐Morales, M. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00450 · Cited by 3
“In vivo studies using rodent models demonstrated cardio protection when GLP-1 (28-36) amide, a byproduct of NEP metabolism of native GLP-1, was infused for 30minutes with recovery of left ventricular pressures and reduced infarct size following ischemic injury.”
BackgroundImpaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD
Ahmadi, A., Gamboa, J. L., Norman, J., Enkhmaa, B., Tucker, M., Bennett, B. J., Zelnick, L. R., Fan, S., Berglund, L., Ikizler, T. A., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000566 · Cited by 3
“40 In fl ammation may contribute to heightened incretin response to an OGTT.”
Materials in Emerging Water Pollutants Detection
Khan, R., Patel, V. R., & Khan, Z. (2019) · Advanced functional materials and sensors · doi:10.1007/978-981-15-0671-0_14 · Cited by 2
Athista, M., Harsiddhi, A., Nachiyar, C. V., & Sunkar, S. (2023) · Medicinal Plants - International Journal of Phytomedicines and Related Industries · doi:10.5958/0975-6892.2023.00008.4 · Cited by 3
Doubles-agonistes, tri-agonistes et multi-agonistes incrétines/glucagon
Phan, F., & Andréelli, F. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.010 · Cited by 3
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Future Drug Treatments for Type 2 Diabetes
Bailey, C. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch79 · Cited by 2
Das, S., Ravi, H., Babu, A., Banerjee, M., Ramasubbu, K., Sivaraman, D., Rajeswari, V. D., Venkatraman, G., & Ramanathan, G. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.017 · Cited by 1
Lee, J. Y., Zhu, C., Boldridge, M. A., Stark, R. L., Bonilla, G. M., Watari, K., Papa, C., Xu, L., Gonzãlez, F., Tang, X., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed3119 · Cited by 3
“While targeting energy intake to improve metabolic health has seen clinical success with incretin-based therapies ( 56 , 57 ), targeting energy expenditure is an alternative, promising path for obesity treatment that could be complementary in combination with existing incretin-based approaches.”
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
“57,66,67 In this context, treatment with survodutide, a dual glucagon and GLP-1 receptor agonist, was associated with HbA1c reductions of up to 0.8%, indicating that the glycemic benefits of GLP-1 receptor agonism are maintained despite concomitant glucagon receptor activation.”
InfluentialDendrobium nobile in the Management of Diabetes and Related Complications
Jain, A., Sarsaiya, S., Gong, Q., Wu, Q., & Shi, J. (2025) · CABI eBooks · doi:10.1079/9781800627987.0006 · Cited by 1
The entero-insular axis: a journey in the physiopathology of diabetes
Malaguarnera, R., Scamporrino, A., Filippello, A., Mauro, S. D., Minardo, A., Purrello, F., & Piro, S. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00025 · Cited by 2
“Certainly, these multi-agonists are absolutely promising for the treatment of DM and obesity [58].”
BackgroundThe Design of a GLP‐1/PYY Dual Acting Agonist
Østergaard, S., Paulsson, J. F., Gerstenberg, M. K., & Wulff, B. S. (2021) · Angewandte Chemie · doi:10.1002/ange.202016464 · Cited by 4
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 2
Baskerville, C. L. (2019) · Minerva Access (University of Melbourne)
Could micro changes in β-cells enable major changes in metabolism?
Capozzi, M. E., & Campbell, J. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102936
“Mimicking the increased gut hormone activity induced by bariatric surgery is a cornerstone driving the development of multi-receptor peptide drugs for the treatment of diabetes [7].”
BackgroundSelf-citationPATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS- CURRENT KNOWLEDGE AND RECENT ADVANCES: MINI REVIEW
Sinha, A., Loganathan, S., Krishnan, S., Mahanta, A., G., N. P., & Bhattacharjee, M. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/5003168
Lard-Blended Vegetable Oil Diet Alleviates Metabolic Syndrome in MicePreprint
Yan, S., Qu, J., Liu, X., Liu, S., Zeng, Y., Zhou, H., Matias, F. B., Wen, L., & Wang, J. (2021) · Research Square · doi:10.21203/rs.3.rs-970689/v1
Ahmad, N., Bahadar, H., Ullah, A., & Hassan, S. M. (2022) · Journal of Bashir Institute of Health Sciences · doi:10.53576/bashir.003.02.0066
Effect of Incretogenic Peptides on Non-Alcoholic Fatty Liver Disease
苏, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361396
Diabesity Treatments Today and Tomorrow
Pavlakis, G., & Goldman, J. D. (2023) · ADCES in Practice · doi:10.1177/2633559x231202497
Andreozzi, F., Mancuso, E., Rubino, M., Salvatori, B., Morettini, M., Monea, G., Göbl, C. S., Mannino, G. C., & Tura, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376530
“Accordingly, the potential of GIP receptor (GIPR) agonism in having independent actions enhancing GLP-1R agonism has led the development of GCGR/GLP-1R coagonists toward multi-receptor coagonists that engage GCGR, GLP-1R, and GIPR as well (19).”
BackgroundInfluentialLi, X., Wang, Y., Chen, Z., & Tan, Z. (2025) · ChemBioChem · doi:10.1002/cbic.202500270
Biological macromolecules as antidiabetic agents
Deore, S. R., Deore, S. R., Surana, V., & Kulkarni, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00007-3
Doppi e tripli agonisti recettoriali nel trattamento del diabete mellito tipo 2
Pizzo, A., Paccagnella, M., Luca, F. D., & Candido, R. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01710-0 · Cited by 1
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738790
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738778
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738787
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738784
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738760
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738757
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738763
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14738793
New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes
Páez, F. G., Barrios, S. Z., Bautista, L. E. C., Chong, L. D. P., & Velazquez, X. G. R. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1009256
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists
Sürmeli, D., Sicinski, K. M., Dinsmore, T. C., Raman, V. S., Montanari, V., Beinborn, M., & Kumar, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00745
Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics
Kostadinova, K. A., Venne, J. L., Krajčovičová, S., Dodgson, J., Hogendorf, W. F. J., Nielsen, T. E., Hymel, D., Bolt, H. L., Collinson, A., Day, J., et al. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71280
Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity
Vishnoi, S., Hudson, S. P., Bhattacharya, S., & Thompson, D. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00903-5 · Cited by 1
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Metadata
- Authors
- Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E.
- Affiliations
- Duke University (US)
- Indiana University Bloomington (US)
- Helmholtz Munich (DE)
- Novo Nordisk Research Center, Indianapolis, Indiana
- Corresponding author
- Campbell, Jonathan E
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-06-13
- Volume
- 39
- Issue
- 5
- Pages
- 719-738
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7263842
- OpenAlex
- W2808030638
- Cited by
- 153
- References
- 164
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 19 · 2021: 30 · 2020: 24 · 2019: 25 · 2018: 4
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- NIH
- American Diabetes Association (1-18-JDF-017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, glucagon, glucose-dependent insulinotropic polypeptide, incretin system, dual receptor agonist, pancreatic beta cells, brain, drug development, hyperglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.